NDA 017453 · Teva Branded Pharm
Proglycem
Diazoxide · Oral
Priority reviewLast checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1976
May 28, 1976
Approved uses
1
Original approval plus efficacy supplements
Registered trials
34
7 Phase 3, 3 recruiting
FAERS reports
737
643 serious, 98 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 6, 2026.
INDICATIONS AND USAGE PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 28, 1976 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- PROGLYCEM · DIAZOXIDE 50MG/ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Diazoxide" as an intervention, any sponsor and status, largest first.
- A Study of Diazoxide Choline in Patients With Prader-Willi SyndromePivotal-lookingCompleted
Soleno Therapeutics, Inc.Industry
NCT03440814 · 127 participants · Start May 9, 2018 · Primary completion May 1, 2020
Drug: DCCR; Placebo for DCCR · For: Prader-Willi Syndrome
Sites: Orange, California; Palo Alto, California; San Diego, California · 29 sites in all
- Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal PeriodPivotal-lookingCompleted
Soleno Therapeutics, Inc.Industry
NCT03714373 · 115 participants · Start Oct 1, 2018 · Primary completion Aug 17, 2023
Drug: DCCR; DCCR and 1 more · For: Prader-Willi Syndrome
Sites: Orange, California; Palo Alto, California; San Diego, California · 28 sites in all
- Regulation of Endogenous Glucose Production by Central KATP ChannelsPivotal-lookingRecruiting
Albert Einstein College of MedicineAcademic, hospital or other
NCT03540758 · 100 participants (planned) · Start Aug 1, 2018 · Primary completion Apr 2027
Drug: Diazoxide; Nicotinic acid and 1 more · For: Diabetes Mellitus; Glucose Metabolism Disorders
Sites: The Bronx, New York
- Diazoxide In the Management Of Hypoglycemic NeonatesPivotal-lookingStatus unknown
University of SaskatchewanAcademic, hospital or other
NCT00994149 · 100 participants (planned) · Start Oct 2009 · Primary completion Oct 2011
Drug: Diazoxide; Ora-plus · For: Infant, Newborn, Diseases; Pregnancy in Diabetics; Infant, Diabetic Mother and 2 more
Sites: Saskatoon, Canada
Essentialis, Inc.Industry
NCT00696475 · 80 participants (planned) · Start Jun 2008 · Primary completion Jan 2009
Drug: Diazoxide choline; Diazoxide choline and 2 more · For: Hypertriglyceridemia
Sites: Los Angeles, California; Jacksonville, Florida; Miami Gardens, Florida · 12 sites in all
- Open-Label Extension Study of DCCR in Patients With Prader-Willi SyndromePivotal-lookingCompleted
Soleno Therapeutics, Inc.Industry
NCT05701774 · 77 participants · Start Jan 31, 2023 · Primary completion Jan 12, 2026
Drug: DCCR · For: Prader-Willi Syndrome
Sites: Orange, California; Palo Alto, California; San Diego, California · 22 sites in all
Rijnstate HospitalAcademic, hospital or other
NCT00631033 · 51 participants · Start Jul 2008 · Primary completion Dec 2011
Drug: Placebo; Diazoxide and 1 more · For: Obesity
Sites: Arnhem, Netherlands
Essentialis, Inc.Industry
NCT01211847 · 44 participants · Start Oct 2010 · Primary completion Sep 2011
Drug: Diazoxide Choline Controlled-Release Tablet; Placebo · For: Hypertriglyceridemia; Dyslipidemia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective134
- hypoglycaemia101
- off label use73
- hyperglycaemia46
- drug ineffective for unapproved indication38
- drug interaction30
- product use in unapproved indication29
- oedema peripheral25
- malignant neoplasm progression23
- nausea23
- death22
- insulinoma22
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 9 |
| 2006 | 6 |
| 2007 | 12 |
| 2008 | 8 |
| 2009 | 8 |
| 2010 | 12 |
| 2011 | 13 |
| 2012 | 16 |
| 2013 | 32 |
| 2014 | 31 |
| 2015 | 56 |
| 2016 | 31 |
| 2017 | 30 |
| 2018 | 31 |
| 2019 | 45 |
| 2020 | 29 |
| 2021 | 55 |
| 2022 | 52 |
| 2023 | 64 |
| 2024 | 63 |
| 2025 | 96 |
| 2026 | 31 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Proglycem (Diazoxide)
2024 spending
$166K
Beneficiaries
18
49 claims
Per beneficiary
$9,197
$12.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,182,624 |
| 2021 | $549,245 |
| 2022 | $254,833 |
| 2023 | $205,884 |
| 2024 | $165,551 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
Miller JL, Gevers E, Bridges N, et al. · J Clin Endocrinol Metab 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study.
Miller JL, Bridges N, Felner EI, et al. · J Clin Endocrinol Metab 2026 · Randomized Controlled Trial
- Comparative meta-analysis of Kabuki syndrome with and without hyperinsulinaemic hypoglycaemia.
Hoermann H, El-Rifai O, Schebek M, et al. · Clin Endocrinol (Oxf) 2020 · Meta-Analysis
- Application of dezocine patient-controlled epidural analgesia in postoperative analgesia in patients with total myomectomy.
Ning FF, Yao TT, Wang XX · World J Clin Cases 2024 · Clinical Trial
- Overview of clinical trials with urapidil.
Schook CE, Radtke H, Wurst W, et al. · Am J Cardiol 1989 · Clinical Trial, Comparative Study
- Pharmacotherapy of preterm labor.
Souney PF, Kaul AF, Osathanondh R · Clin Pharm 1983 · Clinical Trial, Review
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.